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Abstract
Background: A subset of KIT/PDGFRA wild-type gastrointestinal stromal tumors (WT GIST) have been associated
with alteration of the succinate dehydrogenase (SDH) complex II function. A recent report identified four
non-syndromic, KIT/PDGFRA WT GIST harboring compound heterozygous or homozygous mutations in SDHA
encoding the main subunit of the SDH complex II.
Methods: Next generation sequencing was applied on five pediatric and one young adult WT GIST, by whole
exome capture and SOLiD 3-plus system sequencing. The putative mutations were first confirmed by Sanger
sequencing and then screened on a larger panel of 11 pediatric and young adult WT GIST, including 5 in the
context of Carney triad.
Results: A germline p.Arg31X nonsense SDHA mutation was identified in one of the six cases tested by SOLiD
platform. An additional p.D38V missense mutation in SDHA exon 2 was identified by Sanger sequencing in the
extended KIT/PDGFRA WT GIST patients cohort. Western blotting showed loss of SDHA expression in the two cases
harboring SDHA mutations, while expression being retained in the other WT GIST tumors. Results were further
confirmed by immunohistochemistry for both SDHA and SDHB, which showed a concurrent loss of expression of
both proteins in SDHA-mutant lesions, while the remaining WT tumors showed only loss of SDHB expression.
Conclusions: Germline and/or somatic aberrations of SDHA occur in a small subset of KIT/PDGFRA WT GISTs,
outside the Carney’s triad and are associated with loss of both SDHA and SDHB protein expression. Mutations of
the SDH complex II are more particularly associated with KIT/PDGFRA WT GIST occurring in young adults. Although
pediatric GIST consistently display alterations of SDHB protein expression, further molecular studies are needed to
identify the crucial genes involved in their tumorigenesis.
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Background
The majority of gastrointestinal stromal tumors
(GIST) harbor gain-of-function mutations in KIT or
PDGFRA, resulting in the activation of the down-
stream pathways PI3K/AKT, Ras/MAPK, and JAK/
STAT3, and playing a crucial role in tumorigenesis
[1,2]. A subset of GIST lack specific KIT or PDGFRA
mutations and form a heterogeneous group, including
NF1, Carney Triad (CT), Carney-Stratakis Syndrome
(CSS), pediatric and young adult GIST, and a small
proportion (<10%) of sporadic adult GIST [3-8].
The mechanisms involved in the tumorigenesis of
GIST lacking KIT or PDGFRA mutations are still
poorly understood. A subgroup of these GISTs forms
a unique clinicopathological entity, defined by nega-
tive staining for SDHB in addition to exhibiting dis-
tinct morphologic and clinical features [9,10]. Indeed,
such SDH-deficient GISTs account for 5–7.5% of all
gastric GISTs in unselected populations and include
the great majority of pediatric GISTs. They are
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characterized by defects in cellular respiration and ac-
tivation of pseudohypoxia signalling pathways [11].
The succinate dehydrogenase protein complex II
(SDPC II) catalyzes the oxidation of succinate. SDHB
is one of four protein subunits forming succinate
dehydrogenase, the other three being SDHA, SDHC
and SDHD. Loss of SDHB expression results in inhib-
ition of the degradation of Hypoxia Inducing Factors
(HIF), which in turn impairs apoptosis, and induces
angiogenesis and glycolysis [12-15]. Loss of SDHB ex-
pression was first identified in GIST occurring in the
context of Carney triad and in a subset of pediatric
and adult GISTs with similar characteristics [9]. Loss
of SDHB is also seen in WT GIST occuring in the
context of CSS with genlius mutation of SDHB or
SDHC (II). However, such mutations were also found
in about 10% of sporadic GIST lacking KIT or
PDGFRA mutation [11]. The mechanisms involved in
loss of SDHB expression in SDH-deficient GIST with-
out an associated SDHB or SDHC mutations remain
unclear. One possible explanation is loss of function
mutations in the SDHA gene, which have been re-
cently identified in four patients (one pediatric and 3
young adult) with sporadic GIST lacking KIT or
PDGFRA mutations [16,17]. The aim of this study
was to assess globally by next generation sequencing
mutations in the SDH-pathway, as well as determine
the mutational and expression status of SDHA in a
series of syndromic and sporadic GIST without muta-
tions in KIT or PDGFRA.
Methods
Patients
Samples from 17 patients with gastric GIST selected
on the basis of wild-type status for the KIT and
PDGFRA genes were included for analysis. In 6 cases
DNA from frozen tissue was available for next gener-
ation sequencing; in the remaining cases DNA was
available from paraffin embedded material. Thirteen
cases were diagnosed in children (≤18 years) and four
cases in young adults (defined as older than 18 but
younger than age of 30; 3 females and 1 male).
Among the 13 pediatric cases (11 females, 2 males),
five were diagnosed in the context of Carney’s triad
(CT). The mean age at diagnosis for pediatric patients
and young adults was 12 (range 8–18) and 23 years
old (range 21–26), respectively. In all cases, KIT
(exons 9, 11, 13, and 17), PDGFRA (exon 12, 14, 18)
and BRAF (exon 15) genotyping was performed as
previously described [18]. The clinicopathologic and
genotype findings of seven of the pediatric and two
of the young adult GIST cases have been previously
described [19]. The study was approved by the Insti-
tutional Review Board (IRB-protocol 02–060).
Sequencing by Oligonucleotide Ligation and Detection
(SOLiD) and variant detection
Six cases, including five children, one of whom in the
context of CT, and one young adult were analyzed by
the SOLiDTM (Sequencing by Oligonucleotide Ligation
and Detection) platform. This next generation sequen-
cing technology interrogates two bases at a time by
ligation chemistry and detection of one of four colors
associated with those specific two bases. Whole exome
capture was performed on 1–3 μg of high quality gen-
omic DNA using the SureSelect Human All Exon Kit,
which targets 38 MB of exonic sequences, according to
the protocol provided by the manufacturer (Agilent,
Santa Clara, CA, USA). Enriched DNA libraries are then
sequenced on a SOLiD 3plus system (Applied Bio-
systems, Carlsbad, CA, USA), generating 68 million
reads (50 bp). 86% of the targeted region was sequenced
at a 10x-coverage.
The colorspace CSFASTA and QUAL files were first
converted to double encoded FASTQ files which are
then mapped to the target genome (hg19) using BWA
with default options plus the colorspace mode option
(−c). The output SAM files are tagged with read group
ids merge across runs for the same library and then
process with MarkDuplicates from Picard. Overlapping
paired reads are resolved to remove redundant sequence.
Then all the BAM for all samples are merged and
process through the GATK toolkit to first Realign in/dels
and the base Q scores are recalibrated with Recalibration
tool. Paired samples (tumor/normal) are processed in
pairs by muTect and we also run the entire cohort
through the GATK Unified Genotyper to call both SNPs
and in/dels. The variant output file (the VCF file) from
the Unified Genotyper was then annotated using the
SNPeff program with the UCSC RefSeq HG19 database
to annotated the effect of the mutation. The raw output
contained approximately 38,000 events. We then used a
fairly stringent set of criteria to filter these calls. Only
calls marked "PASS" be the Unified Genotype were
retained all other events were filtered out. Further we
removed events that had a non-reference allele fre-
quency (NRAF) less than 10%. We also then removed
any events that were annotated in dbSNP (v132) and
removed those not annotated as HIGH IMPACT by
SNPeff. This lead to a list of five events. For all 5 events
we manually inspected the read pileups in IGV to look
for possible artifacts. Of the 5 only one had no obvious
defects. The other 4 had either strand bias issues and/or
position bias (the variant reads tended to show the
variants at the 3' end of the reads).
Targeted exon resequencing
The mutational status of SDHA (exon 2, 9 and 13) was
assessed by direct Sanger sequencing of genomic DNA.
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Protocols and primers are available on request. Sequence
analysis was performed with Applied Biosystems Se-
quence ScannerTM v1.0.
Western blotting
Western blotting was performed to assess the expression
of SDHA in WT GIST with and without SDHA muta-
tion. Frozen tissue from seven WT GIST (two with
SDHA mutation and five without SDHA mutation) were
homogenized in RIPA buffer supplemented with prote-
ase and phosphatase inhibitors. Electrophoresis and im-
munoblotting were performed on the protein extracts
using 30 μg of protein per sample and the anti-SDHA
rabbit polyclonal antibody (Cell Signaling Technology,
Danvers, MA, USA) was diluted according to the manu-
facturers’ recommendations. Following hybridization
with the secondary anti-rabbit antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), the blots were
incubated with Immun-Star horseradish peroxidase
luminal/enhancer (Bio-Rad, Hercules, CA, USA) and
exposed onto Kodak Biomax MR Film (Eastman Kodak
Co., Rochester, NY, USA).
Immunohistochemistry
Immunohistochemistry (IHC) was applied on all 17 WT
GIST cases tested using SDHA (Abcam, Cambridge, UK,
1:1000) and SDHB (Sigma-Aldrich, St Louis, MO,
1:500), according to manufacturer’s recommendations.
The results of the SDHA and SDHB immunohistochem-
istry were recorded blindly to the KIT, PDGFRA or
SDHA genotyping. One KIT exon 11 mutant GIST from
a young adult patient was used as control. The immu-
noreactivity was scored as negative (loss of expression) if
the tumor cells were negative but the entrapped normal
tissues (endothelial cells) stained positive. Conversely, a
positive result (retained expression) was interpreted if
the tumor cells showed the same intensity staining as
the internal positive control cells. If the tumor showed a
weak intensity of staining, significantly lower than the
normal tissue, the result was interpreted as partial loss
of expression.
Results
Mutation of SDHA is a recurrent event in young adults
with KIT and PDGFRA WT GIST
Massive parallel next-generation sequencing of six
cases of WT GIST (five pediatric and one young
adult) revealed that the GIST from the young adult
patient (22 year-old man, with multinodular gastric
lesions and multiple liver metastases) carried a C to
T transition at nucleotide 206 in SDHA exon 2, a
nonsense mutation resulting in the replacement of ar-
ginine with a stop codon at residue 31 of SDHA,
causing truncation of the peptide chain at residue 30
(p.Arg31X) (Figure 1). This result was then validated
by targeted SDHA exon 2 Sanger sequencing from
the DNA isolated from both tumor and normal tis-
sue, in keeping with a germline mutation. Of note,
the SDHA sequence electropherogram of the normal
DNA revealed equivalent proportion of the wild-type
and the mutated allele (T), whereas tumor DNA con-
tained predominantly the mutated allele (T), indicat-
ing relative loss of the wild-type SDHA allele. This
patient is alive with disease 66 months after the ini-
tial diagnosis, and was treated with multiple kinase
inhibitors with marginal responses, including imatinib,
sunitinib, sorafenib and sirolimus, and being presently
on regorafenib.
Since two prior reports also identified mutations in
SDHA exons 9 and 13 [16,17] in WT GIST, we per-
formed targeted SDHA exons 2, 9 and 13 sequencing
in 11 additional cases of pediatric and young adult
WT GIST. By this method, another young adult WT
GIST (26 year-old woman with bulky intra-peritoneal
and liver metastatic disease) was identified to harbor
a missense mutation in SDHA exon 2 (p. D38V)
(Figure 2). In this latter case, the mutation was
observed only in the tumor and not in the normal
tissue DNA tested. This patient was alive with disease
15 years after the initial diagnosis, preceding the
availability for targeted therapy. No additional muta-
tions in SDHA exons 9 or 13 were identified.
Mutation of SDHA in WT GIST is associated with
concomitant loss of both SDHA and SDHB proteins
expression
To confirm the functional impact of SDHA mutation,
we assessed SDHA protein expression by western
blotting in seven WT GISTs, including three samples
from the two patients with SDHA mutation and four
without SDHA mutation (Figure 3). We found that
SDHA expression was absent in the two cases har-
boring a mutation of SDHA and present in the other
cases. In addition, immunohistochemistry for SDHA
and SDHB was performed. The WT GIST associated
with a germline SDHA mutation showed complete
loss of both SDHA and SDHB protein (Figure 4 A,B),
while the tumor with a somatic, heterozygous SDHA
mutation showed significant decreased in SDHA
immuno-expression, as well as complete loss of
SDHB (Figure 4 C,D). In contrast, strong and diffuse
SDHA reactivity was present in all WT pediatric and
young adult GIST tumors tested without detectable
SDHA mutations, which matched with a complete
loss of SDHB expression (Figure 4 E,F). Furthermore,
both SDHA and SDHB expression was preserved in a
control case of a young adult GIST carrying a KIT
exon 11 deletion (Figure 4 G,H).
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Discussion
The dysregulation of metabolism in cancer has been
established for over 80 years. Indeed, one of the first
identified biochemical hallmarks of cancer cells was a
shift in glucose metabolism from oxidative phosphoryl-
ation to aerobic glycolysis [20]. This metabolic conver-
sion was considered for a long time a consequence
rather than a cause of cancer. However, this vision has
been recently challenged by the finding that a significant
proportion of familial and apparently sporadic paragan-
glioma and pheochromocytoma are related to germline
somatic mutation of genes encoding proteins of SDH
complex II [21-25]. This complex is a membrane-bound
Figure 1 Sanger sequencing validated a nonsense SDHA exon 2 p.Arg31X mutation in both tumor and normal DNA. The SDHA
sequence electropherogram of the tumor DNA contained predominantly the mutated allele (T), indicating relative loss of the wild-type SDHA
allele, compared to the normal DNA.
Figure 2 ABI sequencing showing a somatic mutation in SDHA
exon 2 p. D38V. The normal DNA extracted from this case showed
a wild-type sequence for this locus.
Figure 3 Western blot showing loss of SDHA expression in the
young adult GIST carrying a germline SDHA exon 2 mutation p.
Arg31X (GIST318, primary gastric tumor; GIST353, liver
metastasis), as well as in the young adult GIST carrying a
somatic SDHA exon 2 mutation (GIST118, peritoneal
metastasis). Remaining WT GIST (GIST#289, 491, 507, 517) lacking
SDHA mutations showed preserved SDHA protein expression.
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enzyme complex linked to the respiratory chain and a
member of the Krebs cycle. It consists of 4 subunits: the
flavoprotein subunit (SDHA), the iron-sulfur protein
subunit (SDHB), and the integral membrane protein
subunits (SDHC and SDHD). Mutations of one of the
gene encoding these subunits impair the activity of this
complex and lead to the stabilization and activation of
HIF-1a, which in turn activates cell proliferation and
angiogenesis [12-15].
In addition to paragangliomas and pheochromocyto-
mas, a number of other solid tumors have been asso-
ciated with mutations in genes encoding the succinate
dehydrogenase complex (SDH) complex II. These in-
clude gastrointestinal stromal tumors (GIST) [11,16],
renal tumors [26], thyroid tumors [26-28], testicular
seminoma [29]. The best known association between
SDH complex II germline mutations and other tumors is
represented by the Carney–Stratakis syndrome (or dyad)
which is characterized by the occurrence of KIT and
PDGFRA WT GIST and paraganglioma. This syndrome
is associated with germline point mutations or large
deletions of the genes encoding the SDHB, SDHC or
SDHD subunits [30]. Strikingly, inactivating germline
mutations in SDHB or SDHC genes have been also iden-
tified in sporadic WT GISTs occurring in patients with-
out a personal or family history of paraganglioma [11].
The SDHA gene encodes the major catalytic subunit
of the succinate dehydrogenase complex II. Germline
mutations in SDHA are associated with neurodegenera-
tive diseases such as an early-onset encephalopathy,
known as Leigh syndrome [31-34] and a late-onset optic
atrophy, ataxia and myopathy [35]. Until recently, no
genetic link between SDHA and cancer could be estab-
lished. However, two recent studies allowed the identifi-
cation of SDHA germline mutations in at least 3%
patients with apparently sporadic cases of paraganglioma
or pheochromocytoma [36]. Interestingly, four cases of
sporadic KIT and PDGFRA WT GIST occurring in one
pediatric and three young adult patients have also been
associated with germline mutation of SDHA [16,17]. In
the present study, we investigated a series of 17 appar-
ently sporadic and Carney’s triad-related KIT and
PDGFRA WT GIST for SDHA mutations and found an
additional two cases with mutations in this gene. These
were exclusively present in apparently sporadic cases oc-
curring in young adults. The p.Arg31X SDHA germline
mutation identified in our study leads to a truncated
protein [16]. An identical mutation has been previously
reported in four Dutch patients with paraganglioma and
in one young adult patient with sporadic WT GIST
[16,36]. The second SDHA mutation identified in our
study (p.D38V) has been reported as a single nucleotide
polymorphism. However, none of the other 16 GIST
cases tested showed this change and this mutation was
found only in the tumor DNA, but not in corresponding
normal DNA of the patient. Furthermore, this tumor
showed significant loss of SDHA protein expression by
both western blot and IHC, suggesting a functional im-
pact of this genetic alteration. But since only one source
of normal DNA was analyzed in this patient, we cannot
formally exclude the possibility of germline mosaicism.
Moreover, since we have sequenced only SDHA exons 2,
9 and 13, we cannot exclude also the presence of a
germline mutation in one of the other exons.
Figure 4 Immunohistochemistry showed concomitant loss of SDHA and SDHB expression in SDHA-mutant GIST. Complete loss of
expression for SDHA (A) and SDHB was noted in the germline SDHA-mutant GIST (B), while normal liver showed preserved reactivity. In the
somatic SDHA-mutant GIST there was partial loss of SDHA expression (C), while SDHB staining was absent (D). SDHA expression was retained in a
WT pediatric GIST (E), while SDHB reactivity was lost (F, with internal positive control). In the control KIT exon 11-mutant GIST from a young adult
both SDHA (G) and SDHB protein expressions were preserved (H).
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By performing western blotting, we identified a loss of
SDHA protein expression in the two mutated cases
whereas expression was retained in the non-mutated
cases. This result was expected in the tumor with the p.
Arg31X mutation because this mutation leads to a trun-
cated SDHA protein. Although the p.D38V missense
mutation does not lead to a truncated protein, the
SDHA expression was significantly decreased by IHC
and not detected by Western blot. This result can be
explained by a conformational change of the mutated
SDHA protein compromising the antigenic epitope for
the antibody. Another explanation is that the p.D38V
mutation leads to SDHA protein instability. As indicated
above, since only the hot spot exons 9 and 13 of SDHA
gene were investigated in this case, we cannot exclude
the possibility of a germline mutation in a different exon,
in keeping with a ‘two-hit’ mechanism of loss of func-
tion, implicated in most other SDH-deficient neoplasias.
Further investigations are needed to address this point.
The persistent expression of SDHA protein in SDHA
non-mutated GIST is in accordance with previous studies
which showed consistent SDHA protein expression in
SDHB-, and SDHD-mutated paraganglioma [25,36]. How-
ever, since we have sequenced only exons 2, 9, 13, we can-
not exclude the unlikely possibility of a SDHA mutation
even in cases showing SDHA protein expression. Previous
studies demonstrated that SDHB-, SDHC-, and SDHD-
related paragangliomas and GIST all show loss of SDHB
immunohistochemical expression [11,36]. It was suggested
that absence of functional SDHC or SDHD leads to im-
pairment of complex II formation and degradation of
SDHB. Our results, showing absence of SDHB expression
in SDHA-mutated GIST, are in accordance with this ex-
planation. In contrast, whereas SDHB expression was not
detected in all WT GIST included in our series, all these
tumors (except the two with a mutation of the SDHA
gene) displayed expression of SDHA. These findings sug-
gest that the SDHB protein is degraded when the succin-
ate dehydrogenase complex II is disrupted, whereas the
SDHA protein remains intact.
By pooling our results with those of previous studies
[11,16,17,37], it appears that the majority of mutations
of genes encoding subunits of the SDH complex II iden-
tified in apparently sporadic KIT and PDGFRA WT
GIST occurred in young adults (9 out of 13 patients).
However, the majority of sporadic or syndromic KIT and
PDGFRA WT GIST, occurring in the pediatric or young
adult setting, display loss of SDHB protein [10], suggest-
ing that defects in cellular respiration is a crucial event
even in cases without mutation of the succinate de-
hydrogenase complex II. Therefore, further investigation
are needed to identify the mechanism involved in the al-
teration of the succinate dehydrogenase complex II func-
tion in cases without mutation of SDHA, -B, -C or -D.
Conclusion
In conclusion, this study provides additional evidence
that SDHA is another important gene involved in the
tumorigenesis of a subset of GISTs lacking KIT or
PDGFRA mutation. Although the number of identified
mutation carriers is still low, current observations sug-
gest that mutations of the succinate dehydrogenase com-
plex II are more particularly associated with KIT and
PDGFRA WT GIST occurring in young adults, outside
the Carney’s triad trait. Although pediatric GIST consist-
ently display alterations of SDHB protein expression,
further molecular studies are needed to identify the cru-
cial genetic events involved in their tumorigenesis. Gen-
etic screening for SDHB, C and D germline mutations is
recommended for patients with paraganglioma/pheo-
chromocytoma and SDH deficient GISTs. At the time of
this writing, it remains uncertain whether patients with
SDHA-deficient GIST are also at increased risk for the
tumors associated with SDHx germline mutation. The
penetrance of SHDA mutations is also unknown. There-
fore, further investigations are needed to clarify the
clinical significance of a SDHA germline mutation and
its impact in terms of genetic counseling.
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